Cell-free expression of functional receptor tyrosine kinases.
Sacramento, United States. In Sci Rep, Dec 2014
Here we describe a rapid cell-free and detergent-free co-translation method for producing full-length and functional ERBB2 and EGFR receptor tyrosine kinases supported by water-soluble apolipoprotein A-I based nanolipoprotein particles.
Amsterdam, Netherlands. In Handb Exp Pharmacol, Dec 2014
ApoA-I, the major protein component of HDL, is considered to play an important role in many of the antiatherogenic functions of HDL, most notably reverse cholesterol transport (RCT), and several therapies have been developed to mimic apoA-I function, including administration of apoA-I, mutated variants of apoA-I, and apoA-I mimetic peptides.
HDL in infectious diseases and sepsis.
Cinisello Balsamo, Italy. In Handb Exp Pharmacol, Dec 2014
Pharmacological studies support the benefit of recombinant HDL or apoA-I mimetics during bacterial infection, while apoL-1-nanobody complexes were tested for trypanosome infection.
Control of angiogenesis by AIBP-mediated cholesterol efflux.
San Diego, United States. In Nature, 2013
To prevent cholesterol overload, ATP-binding cassette (ABC) transporters mediate cholesterol efflux from the cells to apolipoprotein A-I (apoA-I) and the apoA-I-containing high-density lipoprotein (HDL).
Lipid-related markers and cardiovascular disease prediction.
In Jama, 2012
OBJECTIVE: To determine whether adding information on apolipoprotein B and apolipoprotein A-I, lipoprotein(a), or lipoprotein-associated phospholipase A2 to total cholesterol and high-density lipoprotein cholesterol (HDL-C) improves cardiovascular disease (CVD) risk prediction.